Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
List view / Grid view
Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Following its latest meeting, the EMA's CHMP has suggested granting marketing authorisation to seven medicines and extending the indications of 15 others.
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.